At what age does Barrett’s esophagus really develop? K. Roark (Chicago)
Has the incidence of Barrett’s esophagus really increased? S.J. Spechler (Dallas)
Has the mortality rate from esophageal cancer really changed? S.J. Sontag (Chicago)
Why is the literature filled with apocalyptic data warning of Barrett’s cancer and the end of the world? S.J. Spechler (Dallas)
Given the best screening/surveillance possible, how much could we expect to decrease esophageal cancer mortality? T. Schnell (Chicago)
Sunday, August 29, 1:45 - 3:35 p.m. - Waterfront I-II
Radio-frequency ablation in treatment of Barrett's esophagus Chairs: C.J. Lightdale(New York) - B.F Overholt (Knoxville)
Comparison of RFA to other ablation modalities. G.Triadafilopoulos (Stanford)
The optimal use of the Halo-360 and Halo-90 devices. R.I. Rothstein (Lebanon)
RFA for dysplastic Barrett's esophagus. N.J. Shaheen (Chapel Hill)
RFA + EMR for management of HGD +IM Ca. H.C. Wolfsen (Jacksonville)
RFA of non-dysplastic Barrett's esophagus
a - Cost-utility analysis. A. Das (Scottsdale)
b - Pathologist’s perspective. R.D. Odze (Boston)
c - Surgeon’s perspective. V. Velanovich (Detroit)
d - Gastroenterologist’s perspective. S. Komanduri (Chicago)
Sunday, August 29, 5:15 - 6:45 p.m. - Waterfront I-II
Molecular Mechanism of Barrett’s Esophagus and Adenocarcinoma
Chairs: R.F. Souza(Dallas) - X. Luke Chen(Durham)
Novel mechanism of bile acid induced DNA damage in Barrett’s esophagus. K. Dvorak (Tucson)
The collaborative roles of BMP-4 and CDX-2 in the development of intestinal metaplasia. K.K. Krishnadath(Amsterdam)
Ectopic expression of transcription factors drive intestinalization in Barrett's Esophagus. J.P. Lynch(Philadelphia)
Bone marrow contribution to Barrett’s metaplasia and cancer. J.M. Houghton(Boston)
Inactivation of squamous transcription factor and activation of intestinal transcription factors in Barrett’s esophagus. X. Luke Chen(Durham)
Monday, August 30, 7:50 - 9:20 a.m. - Waterfront I-II
Barrett's esophagus and animal models
Chairs: T. Miyashita(Kanazawa) - M.K. Gibson(Pittsburgh)
Has suppression of Barrett's carcinogenesis by chemoprevention (administration of proton pump inhibitors, or NSAIDs, or COX-2inhibitors) been proven? B. Jobe(Pittsburgh)
Is Barrett's carcinogenesis related to increased acid level, or bile reflux, or both? Katie Nason
Pathogenesis and molecular mechanism of Barrett's carcinogenesis. K. Mukaisho (Shiga)
Prevention of Barrett’s esophagus and esophageal adenocarcinoma by sonic hedgehog inhibitors—The Levrat model. Ali Zaidi
Chemoprevention for esophageal adenocarcinoma using rat duodeno-esophageal reflux model. T. Fujimura(Kanazawa)
Treatment of Established esophageal adenocarcinoma in the Levrat’s model by using sonic hedghog inhibitors. M.K. Gibson(Pittsburgh)
Monday, August 30,10:30 a.m. - 12:00 p.m.- Waterfront I-II
High Resolution Manometry
Chair: C.P. Gyawali (St Louis)
EGJ anatomy and physiology on HRM. J.O. Clarke(Baltimore)
Ineffective or weak peristalsis: What is normal? R. Tutuian(Bern)
Spastic disorders defined by HRM. M.R. Fox(Zurich)
Achalasia subtypes on HRM: Does it predict outcome? C.P. Gyawali(St Louis)
Has HRM helped with post-fundoplication dysphagia? R.P.Tatum(Seattle)
How many swallows and what position: the appropriate HRM clinical protocol C.P. Gyawali(St Louis)
Monday, August 30, 2:05 - 3:35 p.m. - Waterfront I-II
The Barrett risk in a primary care population Moving towards an improved understanding of the true prevalence and risk
Chair: B.A. Jobe (Pittsburgh) - L. Murray(Belfast)
Framing the topic: L. Murray(Belfast)
Novel techniques for BE screening: Reducing the direct and indirect costs of sedated endoscopy - T. Hoppo(Pittsburgh)
The prevalence of Barrett's esophagus in the "general population": What do we know? G.W Falk(Philadelpjia)
Non-GERD Risk factors of Barrett's esophagus L. B. Gerson(Stanford)
The development of a blood test for Barrett's esophagus: Serum biomarker discovery using proteomics
The Barrett's Esophagus Risk Consortium (BERC) B.A. Jobe(Pittsburgh)
Monday, August 30, 4:25 - 5:55 p.m. - Waterfront I-II
Pathology
Chairs: M. Upton (Seattle) - R.D. Odze (Boston)
To evolve new consensus criteria for pathologic diagnosis of columnar lined esophagus
and to summarize the current controversies. Goals and objectives:
1) To define common terminology for global use by pathologists for describing mucosal types detected in biopsies and resection specimens
2) To propose biopsy strategy optimal for pathologist evaluation
3) To define the controversies regarding cell of origin, utility of biomarkers and areas for future investigation.
Introduction: Controversies regarding definition and terminology of BE M. Upton(Seattle)
What is the role of goblet cells in the development of neoplasia in BE? R.D. Odze(Boston)
What is the role of non-morphologic biomarkers in BE? M. Younes (Houston)
What is the optimal biopsy strategy in patients with BE? P. Chandrasoma(Los Angeles)
What is the role of bone marrow stem cells in BE? M. Vieth(Bayreuth)
Summary and discussion: M.Upton - R.D. Odze
Tuesday, August 31, 7:50 - 9:20- a.m. - Waterfront I-II
Barrett's Esophagus and Health Economics
Chairs: D. Provenzale(Durham)
Overview of the Session: D. Provenzale(Durham)
Economic analysis for the clinician: D. Provenzale(Durham)
Rising incidence of adeno-Ca of the esophagus: B.C. Jacobson(Boston)
Quality of life in Barrett's: L.B. Gerson(Stanford)
Economic analysis of RFA techniques for Barrett's, including a comment on the limited data on the effectiveness of RFA:
Discussion-ALL DP to lead.
Tuesday, August 31,10:30 a.m. - 12:00 p.m. - Waterfront III
Unmet clinical needs in GERD
Chairs: R.H. Hunt(Hamilton) - C. Scarpignato(Parma)
Unmet clinical needs in acid-related disease: an overview. R. H. Hunt (Hamilton)
Unmet needs in healing of esophageal lesions. D. Armstrong(Hamilton)
Unmet needs in symptom control. J. Tack(Leuven)
Unmet needs in inflammation control. G. Nardone (Naples)
New drugs and formulations to address the unmet clinical needs. C. Scarpignato(Parma)
